Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Wednesday, July 17, 2019 from 09:00 – 11:00am ET in New York City.
The meeting will feature short updates by members of the ObsEva management team on the development & market potential of nolasiban, the company’s oral oxytocin receptor antagonist for the improvement of pregnancy and live birth rates following embryo transfer in IVF. This will be followed by a panel discussion with Samuel Pauli, M.D., Reproductive Endocrinologist at Boston IVF; Vicki Schnell, M.D., FACOG, Center of Reproductive Medicine out of Webster, Texas; and Fady I. Sharara, M.D., FACOG, Virginia Center for Reproductive Medicine in Reston, Virginia.
Invitation RSVP: Carolyn Curran
ccurran@lhai.com
A live webcast of the meeting will be accessible under the “Investors” section of ObsEva’s website www.obseva.com, as well as via a direct link here.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4047 Office
+1 646 537 5649 Mobile
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
